Abiopharma

Jim Lang Elected to Halozymes Board of Directors

Oil-Dri Announces Second Highest Quarterly Earnings in History

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Protara Announces Closing of $75 Million Public Offering

Phreesia Announces Third Quarter Fiscal 2026 Results and Introduces Fiscal 2027 Outlook

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock